Evidence-Based Strategies to Improve Access to Therapies for Patients with Spinal Muscular Atrophy
Premiere Date: Friday, December 18, 2020This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- ABP (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, December 18, 2021
Note: Credit Is No Longer Available
 | Claudia A. Chiriboga, MD, MPH, FAAN (Moderator) Professor of Neurology and Pediatrics Division of Pediatric Neurology Columbia University Medical Center New York, NY |
 | Alan D. Pannier, PharmD, MBA Head of Clinical Services SmithRx San Francisco, CA |
Spinal muscular atrophy (SMA) is both a rare disease and the most common fatal genetic disease of infancy. The approval of the first disease-modifying therapy (DMT) for SMA in 2016 revolutionized management, and treatment options have expanded with two additional DMTs approved more recently. However, because SMA is a rare disease, many clinicians and payers have limited knowledge of SMA and the available DMTs, which can contribute to delays in diagnosis and treatment initiation. Evidence-based managed care decision-making is critical in order to enable earlier intervention and optimize patient outcomes in SMA.
In this CMEOCast podcast, expert faculty will help clinicians and payers identify the genetic and clinical assessments used to diagnose SMA and monitor patients over time, apply the latest evidence for efficacy, safety, and cost-effectiveness of SMA therapies, and recognize the importance of the individual patient- and parent/caregiver-related factors in guiding clinical decision-making when managing patients with SMA.
At the end of this CE activity, participants should be able to:
- Identify the genetic and clinical assessments for diagnosing SMA and outcome measures for monitoring disease activity and treatment response.
- Apply the latest clinical evidence to evaluate the efficacy, safety, and long-term cost-effectiveness of approved and emerging therapies for SMA.
- Recognize the individual patient- and parent/caregiver-related factors that guide clinical decision-making in the management of SMA.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize the genetic and clinical assessments for diagnosing SMA and outcome measures for monitoring disease activity and treatment response.
- Describe the latest clinical evidence to evaluate the efficacy, safety, and long-term cost-effectiveness of approved and emerging therapies for SMA.
- Recognize the individual patient- and parent/caregiver-related factors that guide clinical decision-making in the management of SMA.
Supported by an educational grant from Biogen MA, Inc.
Physicians, PAs, nurse practitioners, pharmacists, payers, and managed care decision-makers
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Enduring: 0376-0000-20-169-H01-P
Type: Knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Format
Enduring material
ABP MOC Credit:
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1.5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may chain a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME or a recognized state medical society.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Chiriboga reports that she receives grants from AveXis, Inc.; Biogen; and F. Hoffmann-La Roche. She serves on the advisory committee for AveXis, Inc; Biogen; F. Hoffmann-La Roche; Genentech, USA Inc.; and PTC Therapeutics. She serves as a consultant to F. Hoffmann-La Roche and Genentech, USA Inc.
Dr. Pannier has no disclosures to report.
Michael J. Franks, MSN, AGACNP-BC,FNP-BC (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Rachel Speer, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PD-043-121820-29
